RecruitingPhase 1NCT06414889
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Sponsor
M.D. Anderson Cancer Center
Enrollment
4 participants
Start Date
May 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a procedure called Apheresis, a drug called G-CSF (filgrastim or biosimilar), and others for people with runx1 familial platelet disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGG-CSF (filgrastim or biosimilar)
Given by IV or SC
PROCEDUREApheresis
Given by procedure
DRUGPlerixafor
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06414889